AbCellera Biologics (ABCL) Shares Outstanding (Weighted Average) (2020 - 2026)

AbCellera Biologics has reported Shares Outstanding (Weighted Average) for 7 years, with the latest figure at $303.1 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 1.81% year-over-year to $303.1 million; the trailing twelve-month figure through Mar 2026 stood at $303.1 million (up 1.81% YoY), and the FY2019 full-year result was $151.3 million, changed N/A from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $303.1 million, up from $298.4 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $303.1 million in Q1 2026, with the low at $283.9 million in Q1 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $292.1 million across 5 years, with a median of $292.7 million in 2024.
• Annual changes were most pronounced in 2022 — Shares Outstanding (Weighted Average) increased 5.26% — and 2023, when it increased 1.36%.
• AbCellera Biologics' Shares Outstanding (Weighted Average) stood at $285.3 million in 2022, then gained by 1.46% to $289.5 million in 2023, then gained by 1.53% to $293.9 million in 2024, then climbed by 1.51% to $298.4 million in 2025, then gained by 1.58% to $303.1 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $303.1 million (Q1 2026), $298.4 million (Q3 2025), and $298.5 million (Q2 2025), per Business Quant data.